UroGen Pharma Ltd
UroGen Pharma Ltd (URGN) Options Open Interest
URGN options open interest is 6,367 contracts. The 2-week average daily volume is 260 contracts across the chain.
Read more
Monitoring URGN open interest helps you see where real money is positioned on UroGen Pharma Ltd's options and which strikes are attracting the most commitment from traders. UroGen Pharma Ltd's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor URGN options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising URGN options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect UroGen Pharma Ltd to settle.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer.
The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where URGN open interest is concentrated. Our scanner maps UroGen Pharma Ltd's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade UroGen Pharma Ltd's options open interest as the signal it is, not as an afterthought.
| 45.00 | 0.40 | 4.90 | 2.65 | 102% | +0.4126 | 136 |
| 55.00 | — | 1.15 | 1.15 | 118% | +0.1981 | 59 |
| 40.00 | 1.30 | 4.90 | 3.10 | 60% | +0.6162 | 18 |
| 47.00 | 0.40 | 4.90 | 2.65 | 117% | +0.3783 | 18 |
| 50.00 | 0.05 | 2.05 | 1.05 | 90% | +0.2235 | 12 |
| 47.00 | 5.00 | 9.00 | 7.00 | 81% | -0.7098 | 31 |
| 45.00 | 3.80 | 7.50 | 5.65 | 84% | -0.6224 | 22 |
| 46.00 | 4.00 | 8.00 | 6.00 | 74% | -0.6922 | 20 |
| 41.00 | 0.50 | 4.50 | 2.50 | 67% | -0.4481 | 17 |
| 40.00 | 1.00 | 3.80 | 2.40 | 77% | -0.3942 | 12 |
As of September 25, 2026
Follow the money
Track URGN open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.
Start your 14-day free trial→